Zevra Therapeutics (ZVRA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $9.94, -3.21% vs the prior close of $10.27.
- Volume 593.88K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ZVRA slides 3.2% to $9.94, a 1-month low. Closed at $9.94, -3.21% vs the prior close of $10.27. Day range $9.89–$10.29, opened at $10.29.
ZVRA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ZVRA slides 3.2% to $9.94, a 1-month low
- Closed at $9.94, -3.21% vs the prior close of $10.27. Day range $9.89–$10.29, opened at $10.29.
- Volume was 593.88K shares, 0.6x its 50-day average of 924.97K.
- Price is -13.2% vs its 50-day average ($11.45) and -6.8% vs its 200-day average ($10.67).
- 52-week range $8.01–$15.03; today's close sits at 27% of that range, 33.9% below the 52-week high.
Oct 15, 2026 — ZVRA rises 0.4% to $10.27
- Closed at $10.27, +0.39% vs the prior close of $10.23. Day range $10.22–$10.60, opened at $10.40.
- Volume was 462.40K shares, 0.5x its 50-day average of 931.35K — lighter than usual.
- Price is -10.6% vs its 50-day average ($11.49) and -3.7% vs its 200-day average ($10.66).
- 52-week range $8.01–$15.03; today's close sits at 32% of that range, 31.7% below the 52-week high.
Oct 14, 2026 — ZVRA dips 1.5% to $10.23, 3 down days in a row
- Closed at $10.23, -1.54% vs the prior close of $10.39. Day range $10.08–$10.60, opened at $10.10.
- Volume was 752.60K shares, 0.8x its 50-day average of 941.99K.
- Price is -11.0% vs its 50-day average ($11.50) and -4.0% vs its 200-day average ($10.66).
- 52-week range $8.01–$15.03; today's close sits at 32% of that range, 32.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ZVRA slides 8.2% to $10.39
- Closed at $10.39, -8.22% vs the prior close of $11.32. Day range $10.24–$11.33, opened at $11.33.
- Volume was 1.09M shares, 1.1x its 50-day average of 955.26K.
- Price is -9.7% vs its 50-day average ($11.50) and -2.4% vs its 200-day average ($10.65).
- 52-week range $8.01–$15.03; today's close sits at 34% of that range, 30.9% below the 52-week high.
Oct 12, 2026 — ZVRA dips 0.6% to $11.32
- Closed at $11.32, -0.61% vs the prior close of $11.39. Day range $11.07–$11.39, opened at $11.39.
- Volume was 508.90K shares, 0.5x its 50-day average of 964.50K — lighter than usual.
- Price is -1.5% vs its 50-day average ($11.50) and +6.4% vs its 200-day average ($10.64).
- 52-week range $8.01–$15.03; today's close sits at 47% of that range, 24.7% below the 52-week high.
Oct 9, 2026 — ZVRA jumps 3.5% to $11.39
- Closed at $11.39, +3.55% vs the prior close of $11.00. Day range $10.95–$11.46, opened at $10.95.
- Volume was 730.70K shares, 0.7x its 50-day average of 988.14K.
- Price is -0.6% vs its 50-day average ($11.46) and +7.2% vs its 200-day average ($10.63).
- 52-week range $8.01–$15.03; today's close sits at 48% of that range, 24.2% below the 52-week high.
Oct 8, 2026 — ZVRA dips 0.7% to $11.00
- Closed at $11.00, -0.72% vs the prior close of $11.08. Day range $10.87–$11.09, opened at $11.05.
- Volume was 486.80K shares, 0.5x its 50-day average of 999.26K — lighter than usual.
- Price is -3.7% vs its 50-day average ($11.42) and +3.7% vs its 200-day average ($10.61).
- 52-week range $8.01–$15.03; today's close sits at 43% of that range, 26.8% below the 52-week high.
Oct 7, 2026 — ZVRA jumps 3.3% to $11.08, 3 up days in a row
- Closed at $11.08, +3.26% vs the prior close of $10.73. Day range $10.57–$11.38, opened at $10.68.
- Volume was 936.30K shares, 0.9x its 50-day average of 1.01M.
- Price is -2.8% vs its 50-day average ($11.40) and +4.5% vs its 200-day average ($10.60).
- 52-week range $8.01–$15.03; today's close sits at 44% of that range, 26.3% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — ZVRA ends flat (+0.3%) to $10.73
- Closed at $10.73, +0.28% vs the prior close of $10.70. Day range $10.44–$10.88, opened at $10.76.
- Volume was 614.60K shares, 0.6x its 50-day average of 1.03M — lighter than usual.
- Price is -5.7% vs its 50-day average ($11.37) and +1.4% vs its 200-day average ($10.58).
- 52-week range $8.01–$15.03; today's close sits at 39% of that range, 28.6% below the 52-week high.
Oct 5, 2026 — ZVRA jumps 7.1% to $10.70
- Closed at $10.70, +7.11% vs the prior close of $9.99. Day range $10.00–$10.81, opened at $10.01.
- Volume was 1.98M shares, 1.7x its 50-day average of 1.13M.
- Price is -5.7% vs its 50-day average ($11.35) and +1.2% vs its 200-day average ($10.57).
- 52-week range $8.01–$15.03; today's close sits at 38% of that range, 28.8% below the 52-week high.
Oct 2, 2026 — ZVRA dips 1.9% to $9.99, a 1-month low, 3 down days in a row
- Closed at $9.99, -1.87% vs the prior close of $10.18. Day range $9.85–$10.24, opened at $10.24.
- Volume was 950.60K shares, 0.8x its 50-day average of 1.13M.
- Price is -11.8% vs its 50-day average ($11.33) and -5.4% vs its 200-day average ($10.56).
- 52-week range $8.01–$15.03; today's close sits at 28% of that range, 33.6% below the 52-week high.
- That makes 3 straight losses.
ZVRA latest news & SEC filings
Every SEC filing by or about ZVRA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mcfarlane Neil F. converted options/RSUs into 50,000 shares on Oct 10, 2026; now holds 437,225
- Mcfarlane Neil F. sold 20,000 shares at $11.25 (≈$224.95K) on Oct 12, 2026; now holds 417,225
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Thompson Rahsaan sold 42,666 shares at $11.13 (≈$474.87K) on Aug 14, 2026
- Thompson Rahsaan sold 42,666 shares at $11.13 (≈$474.87K) on Aug 14, 2026
- Thompson Rahsaan sold 42,666 shares at $11.13 (≈$474.87K) on Aug 14, 2026
- Thompson Rahsaan sold 42,666 shares at $11.13 (≈$474.87K) on Aug 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Watton Corey Michael sold 12,300 shares at $11.25 (≈$138.38K) on Aug 10, 2026
- Watton Corey Michael sold 12,300 shares at $11.25 (≈$138.38K) on Aug 10, 2026
- Watton Corey Michael sold 12,300 shares at $11.25 (≈$138.38K) on Aug 10, 2026
- Watton Corey Michael sold 12,300 shares at $11.25 (≈$138.38K) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: $8.75M (prior year $74.71M) (-88.3% vs Jun 30, 2025)
- Diluted EPS: $0.14 (prior year $1.21) (-88.4% vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Things to know before you trade ZVRA
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Mar 9, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.50% (largest 8.2%).
- Liquidity: about 881.53K shares (≈$8.76M) trade per day on average.
- 52-week position: $9.94 vs a range of $8.01–$15.03 (27% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Rahsaan Thompson sold 42,666 shares on Aug 14, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 5, 2026.
- Share count: 59.38M shares outstanding (Jul 31, 2026), +5.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ZVRA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 10.29 | 10.29 | 9.89 | 9.94 | 593.88K |
| Oct 15, 2026 | 10.40 | 10.60 | 10.22 | 10.27 | 462.40K |
| Oct 14, 2026 | 10.10 | 10.60 | 10.08 | 10.23 | 752.60K |
| Oct 13, 2026 | 11.33 | 11.33 | 10.24 | 10.39 | 1.09M |
| Oct 12, 2026 | 11.39 | 11.39 | 11.07 | 11.32 | 508.90K |
| Oct 9, 2026 | 10.95 | 11.46 | 10.95 | 11.39 | 730.70K |
| Oct 8, 2026 | 11.05 | 11.09 | 10.87 | 11.00 | 486.80K |
| Oct 7, 2026 | 10.68 | 11.38 | 10.57 | 11.08 | 936.30K |
| Oct 6, 2026 | 10.76 | 10.88 | 10.44 | 10.73 | 614.60K |
| Oct 5, 2026 | 10.01 | 10.81 | 10.00 | 10.70 | 1.98M |
| Oct 2, 2026 | 10.24 | 10.24 | 9.85 | 9.99 | 950.60K |
| Oct 1, 2026 | 10.91 | 10.97 | 10.15 | 10.18 | 1.30M |
| Sep 30, 2026 | 11.37 | 11.38 | 10.94 | 10.97 | 1.82M |
| Sep 29, 2026 | 11.28 | 11.50 | 11.20 | 11.34 | 1.35M |
| Sep 28, 2026 | 11.01 | 11.36 | 10.89 | 11.30 | 742.50K |
| Sep 25, 2026 | 11.29 | 11.30 | 11.01 | 11.04 | 677.90K |
| Sep 24, 2026 | 11.28 | 11.31 | 11.06 | 11.26 | 594.00K |
| Sep 23, 2026 | 11.58 | 11.58 | 11.15 | 11.32 | 735.00K |
| Sep 22, 2026 | 11.85 | 11.88 | 11.51 | 11.58 | 600.40K |
| Sep 21, 2026 | 11.72 | 11.88 | 11.52 | 11.67 | 714.50K |
About Zevra Therapeutics
Zevra Therapeutics (ZVRA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1434647.
ZVRA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Thomas Anderson | Director | Jun 18, 2026 |
| John B Bode | Director | Mar 26, 2026 |
| Douglas W Calder | Director | Jun 18, 2026 |
| Tamara A Favorito | Director | Jun 18, 2026 |
| Neil F. Mcfarlane | President and CEO | Feb 10, 2026 |
| Alicia Secor | Director | Jun 18, 2026 |
| Alvin Shih | Director | Jun 18, 2026 |
| Corey Michael Watton | Director | Aug 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Neil F. Mcfarlane | President and CEO | Feb 10, 2026 |
| Adrian W Quartel | Chief Medical Officer | Feb 2, 2026 |
| Justin A Renz | CFO | Mar 19, 2026 |
| Timothy J. Sangiovanni | SVP, Finance & Corp Controller | May 29, 2026 |
| Joshua Schafer | CCO | Feb 4, 2026 |
| Rahsaan Thompson | Chief Legal & Compliance | Aug 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Rahsaan Thompson | Sale | 42,666 | $11.13 |
| Aug 14, 2026 | Rahsaan Thompson | Sale | 42,666 | $11.13 |
| Aug 14, 2026 | Rahsaan Thompson | Sale | 42,666 | $11.13 |
| Aug 14, 2026 | Rahsaan Thompson | Sale | 42,666 | $11.13 |
| Aug 10, 2026 | Corey Michael Watton | Sale | 12,300 | $11.25 |
| Aug 10, 2026 | Corey Michael Watton | Sale | 12,300 | $11.25 |
| Aug 10, 2026 | Corey Michael Watton | Sale | 12,300 | $11.25 |
| Aug 10, 2026 | Corey Michael Watton | Sale | 12,300 | $11.25 |
| Jun 22, 2026 | Rahsaan Thompson | Sale | 34,557 | $12.68 |
| Jun 22, 2026 | Rahsaan Thompson | Sale | 34,557 | $12.68 |
| Jun 22, 2026 | Rahsaan Thompson | Sale | 34,557 | $12.68 |
| Jun 22, 2026 | Rahsaan Thompson | Sale | 34,557 | $12.68 |
| May 11, 2026 | Rahsaan Thompson | Sale | 1,794 | $11.30 |
| May 11, 2026 | Rahsaan Thompson | Sale | 1,794 | $11.30 |
| May 11, 2026 | Rahsaan Thompson | Sale | 1,794 | $11.30 |
ZVRA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $83.23M | 1.35 | $-1.60M |
| Dec 31, 2024 | — | $-105.51M | -2.28 | $-69.67M |
| Dec 31, 2023 | — | $-46.05M | — | $-33.53M |
| Dec 31, 2022 | — | $-26.77M | — | $-18.72M |
| Dec 31, 2021 | — | $-8.55M | -2.11 | $10.44M |
Latest balance sheet: total assets $302.71M, total liabilities $85.06M, cash $145.32M (as of Jun 30, 2026).
ZVRA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $10.53 |
| May 6, 2026 | 8-K Item 2.02 (results) | $11.25 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $9.12 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $10.07 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $11.76 |
| May 13, 2025 | 8-K Item 2.02 (results) | $7.87 |
| Apr 7, 2025 | 8-K Item 2.02 (results) | $7.05 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $8.07 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $8.57 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ZVRA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.